New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naïve resistance to pan-HDACi in diffuse large B cell lymphoma' by Havas et al.

• This editorial provides a brief overview of the role of HDACs in diffuse large B-cell lymphoma (DLBCL). • Possible mechanisms of HDAC inhibitor resistance in DLBCL are discussed in detail. • It highlights the need for developing HDAC isoform-specific inhibitors. • Additional combinatory regimens and dual-specificity inhibitors may increase the therapeutic efficacy of HDAC inhibition in this aggressive lymphoma.